Cutaneous T-Cell Lymphoma (CTCL) Emerging and Marketed Drugs Assessment According to DelveInsight’s evaluation, globally, more than 25 key...

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late...

SAN DIEGO, Aug. 19, 2024 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class,...

Health consequences of over active xanthine oxidase may accelerated PKD progression CALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) — XORTX...

CAMBRIDGE, Mass., Aug. 13, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...

AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second...

Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab...

Appendix cancer, a rare and often silent disease, is drawing attention from medical experts due to its challenging diagnosis and potential impact on...

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in...